Keros Therapeutics, Inc. KROS
10.83 USD +0.07 (+0.65%)
At closeNov 3, 2026, 4:00 PM EST
10.83 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
10.78 Day range 11.11
9.69 52-week range 22.55
- YTD
- -46.81%
- 1 year
- -28.84%
Financial health
Altman Z-Score
2.62 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
Valuation
P/E 8.7×
FY 2018 5y median -7.6× FY 2025
P/S 3.1×
FY 2018 5y median 67.9× FY 2025
P/B 2.5×
FY 2018 5y median 3.5× FY 2025
P/FCF 7.2×
FY 2018 5y median -9.2× FY 2025
EV/EBITDA 5.2×
FY 2018 5y median -5.6× FY 2025
EV/Sales 2.0×
FY 2018 5y median 14.5× FY 2025
FCF Yield 14.0%
FY 2018 5y median -5.9% FY 2025
Profitability
Gross Margin 99.4%
FY 2018 5y median 100.0% FY 2025
Operating Margin 28.9%
FY 2018 5y median -280.5% FY 2025
Net Margin 35.7%
FY 2018 5y median -292.3% FY 2025
ROE 28.7%
FY 2018 5y median -32.8% FY 2025
ROIC 20.9%
FY 2018 5y median -35.7% FY 2025
ROA 25.7%
FY 2018 5y median -30.4% FY 2025
Growth (YoY)
Revenue 6775.0%
FY 2018 FY 2025
Operating Income 133.5%
FY 2018 FY 2025
EPS (diluted) 146.0%
FY 2018 FY 2025
Free Cash Flow 165.1%
FY 2018 FY 2025
Financial Health
Current Ratio 15.5×
FY 2018 5y median 17.3× FY 2025
Quick Ratio 15.5×
FY 2018 5y median 17.3× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA -2.9×
FY 2018 5y median 2.6× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
